Debiopharm licenses SunRock Biopharma’s anti-HER3/HER2 antibody to explore the full potential of bispecific ADC Debio 2512

CAR-T Digest - August 2020

30 September 2025: Debiopharm licenses SunRock Biopharma’s anti-HER3/HER2 antibody to explore the full potential of bispecific ADC Debio 2512

Debiopharm licensed SunRock Biopharma’s bispecific HER3/HER2 antibody SRB21 to develop a new ADC candidate named Debio 2512, using its proprietary MultiLINK linker technology
The partnership builds on an agreement announced in 2023, aiming to create next-generation bispecific ADCs that enhance efficacy, specificity, and overcome resistance mechanisms in HER-driven cancers.
Debiopharm will apply its “Trifecta” approach (bispecific antibody + smart payload selection + proprietary linker) to maximize targeted delivery while reducing off-target effects
The deal marks a milestone for SunRock Biopharma, validating its bispecific antibody platform, while offering hope for patients with HER2-resistant or recurrent cancers